Current and future strategies in the treatment of childhood pulmonary hypertension

Progress in Pediatric Cardiology

Volumn 12, Issue 3, 2001, Pages 289-318

  Wessel, David L ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Congenital heart disease; Elastase inhibitors; Endothelin receptor blockers; Gene transfer therapy; Intensive care; Nitric oxide; Phosphodiesterase inhibitors; Prostacyclin; Vascular endothelial growth factor

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ELASTASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; INOTROPIC AGENT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXYGEN; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; VASCULOTROPIN; VASODILATOR AGENT; WARFARIN;

ALKALOSIS; ANIMAL MODEL; BLOOD VESSEL; CARDIOPULMONARY BYPASS; CHILDHOOD; CONFERENCE PAPER; CONGENITAL HEART DISEASE; DISEASE SEVERITY; ENDOTHELIUM CELL; GENE THERAPY; GENE TRANSFER; GENETICS; GROWTH; HEMODYNAMICS; HUMAN; HYPERVENTILATION; INTENSIVE CARE; LUNG DISEASE; LUNG VOLUME; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SEDATION; VASCULAR ENDOTHELIUM;

EID: 0035022360     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1058-9813(01)00075-3     Document Type: Conference Paper

References (280)

1. Repair of truncus arteriosus in the neonate
2. Effect of baffle fenestration on outcome of the modified Fontan operation
3. Blunting of stress responses in the pulmonary circulation of infants by fentanyl
4. Halothane-morphine compared to high-dose sufentanil for anesthesia and postoperative analgesia in neonatal cardiac surgery
5. Pulmonary and systemic hemodynamic responses to fentanyl in infants
6. Pulmonary and systemic hemodynamic effects of nitrous oxide in infants with normal and elevated pulmonary vascular resistance
7. Hemodynamic effects of ketamine in children with congenital heart disease
8. Hemodynamic effects of ketamine in children undergoing cardiac catheterization
9. The pulmonary hemodynamic response to perioperative anesthesia in the treatment of high-risk infants with congenital diaphragmatic hernia
10. Fentanyl-air-oxygen anesthesia for ligation of patent ductus arteriosus in preterm infants
11. Fentanyl- and sufentanil- oxygen- pancuronium anesthesia for cardiac surgery in infants
12. Hemodynamic and anesthetic effects of sufentanil as the sole anesthetic for pediatric cardiovascular surgery
13. Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery
14. Anesthesia for hypoplastic left heart syndrome: high dose fentanyl in 30 neonates
15. Randomized trial of fentanyl anesthesia in preterm neonates undergoing surgery: effects on the stress response
16. Pulmonary and systemic hemodynamic responses to ketamine in infants with normal and elevated pulmonary vascular resistance
17. Pharmacokinetics of alfentanil before and after cardiopulmonary bypass in pediatric patients undergoing cardiac surgery: part I
18. Effect of anesthetic induction regimens on oxygen saturation in cyanotic congenital heart disease
19. The dose response to fentanyl in neonatal surgery [Abstract]
20. Pharmacokinetics of continuous infusions of fentanyl in critically ill children
21. Plasma fentanyl levels in infants undergoing extracorporeal membrane oxygenation
22. Alfentanil-induced rigidity in newborn infants
23. Response to the pulmonary circulation to hypoxia and H+ ion changes
24. 2 on pulmonary and systemic hemodynamics after surgery in children with congenital heart disease and pulmonary hypertension
25. Pulmonary vascular resistance in infants after cardiac surgery: role of carbon dioxide and hydrogen ion
26. The independent effects of hyperventilation, tolazoline, and dopamine on infants with persistent pulmonary hypertension
27. Physiologic factors affecting pulmonary artery pressure in infants with persistent pulmonary hypertension
28. Efficacy and neurologic outcome of profound hypocapneic alkalosis for the treatment of persistent pulmonary hypertension in infancy
29. Long-term follow-up of newborns with persistent pulmonary hypertension
30. The effects of prolonged hyperventilation on cerebral metabolism
31. Results of 102 cases of complete repair of congenital heart defects in patients weighing 700 to 2500 grams
32. Pain and its effects in the human neonate and fetus
33. Pulmonary vascular response to oxygen in infants with severe bronchopulmonary dysplasia
34. Effects of oxygen on pulmonary and systemic hemodynamics in infants after cardiopulmonary bypass
35. Distribution of blood flow in isolated lung: relation to vascular and alveolar pressures
36. The onset of breathing at birth stimulates pulmonary vascular prostacyclin synthesis
37. Pulmonary metabolism of prostaglandins and vasoactive peptides
38. Physiologic effects of increasing hemoglobin concentration in left-to-right shunting in infants with ventricular septal defects
39. Selective pulmonary and systemic vasodilator effects of amrinone in children: new therapeutic implications
40. Hemodynamic effects of amrinone in children after cardiac surgery
41. Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery
42. Use of amrinone in cardiac surgery patients
43. Amrinone and dobutamine as primary treatment of low cardiac output syndrome following coronary artery surgery: a comparison of their effects on hemodynamics and outcome
44. The pharmacokinetics of milrinone in pediatric patients after cardiac surgery
45. Pharmacokinetics and side effects of milrinone in infants and children after open heart surgery
46. Pulmonary and systemic hemodynamic effects of central nervous and left atrial sympathomimetic drug administration in the dog
47. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs
48. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension [see comments]
49. Endothelin-1 levels in infants with pulmonary hypertension receiving extracorporeal membrane oxygenation
50. Circulating endothelin in children with congenital heart disease
51. Effect of inhaled nitric oxide on endothelin-1 and cyclic guanosine 5′-monophosphate plasma concentrations in newborn infants with persistent pulmonary hypertension
52. Endothelin receptor blockade prevents the rise in pulmonary vascular resistance after cardiopulmonary bypass in lambs with increased pulmonary blood flow
53. Combination therapy for pulmonary hypertension: a glimpse into the future?
54. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
55. Nitric oxide release accounts for the biologic activity of endothelium-derived relaxing factor
56. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide
57. Vascular endothelial cells synthesize nitric oxide from L-arginine
58. Selective pulmonary vasodilation by inhaled nitric oxide is due to hemoglobin inactivation
59. Pulmonary vasodilatory effects of 12 and 60 parts per million inhaled nitric oxide in children with ventricular septal defect
60. Inhaled nitric oxide and hemodynamic evaluation of patients with pulmonary hypertension before transplantation
61. Inhaled nitric oxide in children with pulmonary hypertension and congenital mitral stenosis
62. Use of inhaled nitric oxide and acetylcholine in the evaluation of pulmonary hypertension and endothelial function after cardiopulmonary bypass
63. Inhaled nitric oxide in congenital heart disease
64. Inhaled nitric oxide in the treatment of postoperative graft dysfunction after lung transplantation
65. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn
66. Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide
67. Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose response
68. Inhaled nitric oxide for the adult respiratory distress syndrome
69. Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilation
70. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man
71. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics
72. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans
73. Role of endothelium in the maintenance of low pulmonary vascular tone in normal children
74. Endogenous nitric oxide and pulmonary vascular tone in the neonate
75. Regulation of pulmonary vascular resistance by endogenous and exogenous nitric oxide
76. Endothelium-derived nitric oxide regulates systemic and pulmonary vascular resistance during acute hypoxia in humans
77. Endothelium-derived relaxing factor and the pulmonary circulation
78. Abnormalities in von Willebrand factor and antithrombin III after cardiopulmonary bypass operations for congenital heart disease
79. Effects of cardiopulmonary bypass and circulatory arrest on endothelium-dependent vasodilatation in the lung
80. Pulmonary sequelae of prolonged total venoarterial bypass: Evaluation with a new experimental model
81. Pulmonary vasodilation by inhaled nitric oxide after endothelial injury
82. Inhaled endothelium derived-relaxing factor (EDRF) in primary hypertension (PPH)
83. Inhaled nitric oxide reverses hypoxic vasoconstriction in <100 micron canine pulmonary microvessels
84. Sites of vasodilation by inhaled nitric oxide vs. sodium nitroprusside in endothelin-constricted isolated rat lungs
85. Endothelium-derived nitric oxide plays a larger role in pulmonary veins than in arteries of newborn lambs
86. Inhaled nitric oxide: diameter response patterns in feline small pulmonary arteries and veins
87. Site of pulmonary vasodilation by inhaled nitric oxide in the perfused lung
88. Inhaled nitric oxide lowers pulmonary capillary pressure and changes longitudinal distribution of pulmonary vascular resistance in patients with acute lung injury
89. Inhaled nitric oxide selectively decreases pulmonary vascular resistance following acute massive pulmonary microembolism in piglets
90. Use of inhaled nitric oxide to reverse flow through a patent foramen ovale during pulmonary embolism
91. Nitric oxide improves hypoxaemia following reperfusion oedema after pulmonary thromboendarterectomy
92. Inhaled nitric oxide as an adjunct to pulmonary thromboendarterectomy
93. Inhaled nitric oxide inhibits platelet aggregation after pulmonary embolism in pigs
94. Pulmonary vascular disease in different types of congenital heart disease. Implications for interpretation of lung biopsy findings in early childhood
95. The pathology of hypertensive pulmonary vascular disease: a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects
96. Pulmonary vascular disease with congenital heart lesions: pathologic features and causes
97. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease
98. Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators
99. Correlations of lung morphology, pulmonary vascular resistance, and outcome in children with congenital heart disease
100. Effect of breathing oxygen in patients with severe pulmonary vascular obstructive disease
101. Pulmonary vascular resistance in complete atrioventricular septal defect. A comparison between children with and without Down's syndrome
102. Modification of pulmonary hypertension secondary to congenital heart disease by prostacyclin therapy
103. Potential for reversibility of pulmonary vascular obstructive disease in children after cardiac transplantation
104. Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance
105. Preoperative prediction of postoperative pulmonary arteriolar resistance after surgical repair of complete atrioventricular canal defect
106. Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease
107. The neonate with critical congenital heart disease: repair-a surgical challenge
108. Intensive care
109. Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants: a comparison of low-flow cardiopulmonary bypass versus circulatory arrest
110. Pulmonary hypertensive crises following surgery for congenital heart defects in young children
111. Diagnosis and management of postoperative pulmonary hypertensive crisis
112. Changes in pericardial surface pressure during pulmonary hypertensive crises after cardiac surgery
113. Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart defects
114. Total anomalous pulmonary venous return. Prenatal damage to pulmonary vascular bed and extrapulmonary veins
115. Rebound pulmonary hypertension after inhalation of nitric oxide
116. Pulmonary vascular disease in total anomalous pulmonary venous drainage
117. Structural study of pulmonary circulation and of heart in total anomalous pulmonary venous return in early infancy
118. Significance of the pulmonary vascular bed in congenital heart disease
119. Diagnostic use of inhaled nitric oxide after neonatal cardiac operations
120. Inhaled nitric oxide for children with congenital heart disease and pulmonary hypertension
121. Continuous low dose inhaled nitric oxide for treatment of severe pulmonary hypertension after cardiac surgery in paediatric patients
122. Very low dose inhaled nitric oxide: A selective pulmonary vasodilator after operations for congenital heart disease
123. Surgical repair of transposition of the great arteries in neonates with persistent pulmonary hypertension
124. Inhaled nitric oxide for the postoperative management of Fontan-type operations
125. Clinical applications of gaseous nitric oxide
126. Intraoperative use of inhaled low-dose nitric oxide
127. Inhaled nitric oxide in pulmonary hypertension after total repair of total anomalous pulmonary venous return
128. Transient effects of inhaled nitric oxide for prolonged postoperative treatment of hypoxemia after surgical correction of total anomalous pulmonary venous return
129. Relief of severe pulmonary hypertension after closure of a large ventricular septal defect using low dose inhaled nitric oxide
130. Outcome-associated factors in pediatric patients treated with extracorporeal membrane oxygenator after cardiac surgery
131. Extracorporeal membrane oxygenation for cardiac failure after congenital heart operation
132. Nitric oxide might reduce the need for extracorporeal support in children with critical postoperative pulmonary hypertension
133. Elevated pulmonary vascular resistance and cardiac transplantation
134. Analysis of morbid events and risk factors for death after cardiac transplantation
135. Determinants of operative risk in human heart transplantation
136. Improved survival following pediatric cardiac transplantation in high-risk patients
137. Preoperative pulmonary hemodynamics and early mortality after orthotopic cardiac transplantation: the Pittsburgh experience
138. Analysis and predictors of pulmonary vascular resistance after cardiac transplantation
139. 1, and sodium nitroprusside
140. Preliminary experience with inhaled nitric oxide for acute pulmonary hypertension after heart transplantation
141. Inhaled nitric oxide for right ventricular failure after heart transplantation
142. Low doses of inhaled nitric oxide in heart transplant recipients
143. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension
144. Inhaled nitric oxide versus inhaled prostacyclin and intravenous versus inhaled prostacyclin in acute respiratory failure with pulmonary hypertension in piglets
145. Effects of inhaled prostacyclin as compared with inhaled nitric oxide on right ventricular performance in hypoxic pulmonary vasoconstriction
146. Nitric Oxide is superior to prestacyclin for pulmonary hypertension after cardiac operations
147. Combined therapy with inhaled nitric oxide and intravenous prostacyclin in an infant with alveolar-capillary dysplasia
148. Nitric oxide and prostacyclin lower suprasystemic pulmonary hypertension after cardiopulmonary bypass
149. Atrial natriuretic peptide and nitric oxide in children with pulmonary hypertension after surgical repair of congenital heart disease
150. Dipyrimadole augmentation of response to nitric oxide
151. Effective control of refractory pulmonary hypertension after cardiac operations
152. Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats
153. Inhaled nitric oxide improves hepatic tissue oxygenation in right ventricular failure: value of venous oxygen saturation monitoring
154. Inhaled nitric oxide for the management of acute right ventricular failure in patients with a left ventricular assist system
155. The pulmonary effect of nitric oxide synthase inhibition following endotoxemia in a swine model
156. Effect of inhaled nitric oxide on pulmonary function after sepsis in a swine model
157. Treatment of respiratory failure in an infant with bronchopulmonary dysplasia infected with respiratory syncytial virus using inhaled nitric oxide and high frequency ventilation
158. Inhaled nitric oxide for a severe respiratory syncytial virus infection in an infant with bronchopulmonary dysplasia
159. PFC syndrome (persistence of the fetal circulation)
160. Persistent pulmonary vascular obstruction in newborn infants
161. Persistent pulmonary hypertension of the newborn infant
162. Advances in the treatment of persistent pulmonary hypertension of the newborn
163. Inhaled nitric oxide for persistent pulmonary hypertension of the newborn. The physiology matters!
164. Randomized, multicenter trial of inhaled nitric oxide and high frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn
165. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn
166. Extracorporeal circulation in neonatal respiratory failure: a prospective randomized study
167. Extracorporeal membrane oxygenation and conventional medical therapy in neonates with persistent pulmonary hypertension of the newborn: a prospective randomized study
168. UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation
169. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure
170. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn
171. Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn
172. Near fatal pulmonary hypertension after surgical repair of congenital diaphragmatic hernia. Successful use of inhaled nitric oxide
173. Inhaled nitric oxide in congenital diaphragmatic hernia
174. Pathophysiology of congenital diaphragmatic hernia VIII: inhaled nitric oxide requires exogenous surfactant therapy in the lamb model of congenital diaphragmatic hernia
175. Perfluorocarbon-associated gas exchange improves pulmonary mechanics, oxygenation, ventilation, and allows nitric oxide delivery in the hypoplastic lung congenital diaphragmatic hernia lamb model
176. Inhaled nitric oxide in congenital hypoplasia of the lungs due to diaphragmatic hernia or oligohydramnios
177. Novel therapies for acute respiratory failure
178. In acute lung injury, inhaled nitric oxide improves ventilation-perfusion matching, pulmonary vascular mechanics, and transpulmonary vascular efficiency
179. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome
180. Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome
181. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome
182. PGI2 aerosol versus nitric oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction
183. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group
184. Effects of inhaled nitric oxide on right ventricular function in severe acute respiratory distress syndrome
185. Effects of inhaled nitric oxide on right ventricular function in endotoxin shock
186. Nitric oxide improves transpulmonary vascular mechanics but does not change intrinsic right ventricular contractility in an acute respiratory distress syndrome model with permissive hypercapnia
187. Single lung transplantation-alternative indications and techniques
188. Pediatric lung transplantation the years 1985 to 1992 and the clinical trial of FK506
189. Current trends in lung transplantation. Lobar transplantation and expanded use of single lungs
190. Lung transplantation analysis of thirty-six consecutive procedures performed over a twelve-month period
191. Single lung transplantation for pulmonary hypertension
192. Successful treatment of life-threatening acute reperfusion injury after lung transplantation with inhaled nitric oxide
193. Avoidance of cardiopulmonary bypass during bilateral sequential lung transplantation using inhaled nitric oxide
194. Inhaled nitric oxide reveals and attenuates endothelial dysfunction after lung transplantation
195. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo
196. Inhaled nitric oxide in sickle cell disease with acute chest syndrome
197. Dose-response relationship for inhaled nitric oxide in experimental pulmonary hypertension in sheep
198. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin
199. Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome
200. Inhaled nitric oxide in acute respiratory failure: dose-response curves
201. Inhaled nitric oxide in infants with developing or established chronic lung disease
202. Nitric oxide inhalation: effects on the ovine neonatal pulmonary and systemic circulations
203. Inhaled nitric oxide: dose response and the effects of blood in the isolated rat lung
204. Effect of inhaled nitric oxide during group B streptococcal sepsis in piglets
205. Higher does of inhaled nitric oxide might be less effective in improving oxygenation in a patient with interstitial pulmonary fibrosis
206. Dose-response to inhaled nitric oxide in acute hypoxemic respiratory failure of newborn infants: a preliminary report
207. Inhaled nitric oxide in neonatal and pediatric acute respiratory distress syndrome: dose response, prolonged inhalation, and weaning
208. Kinetics of methaemoglobin and serum nitrogen oxide production during inhalation of nitric oxide in volunteers
209. A mechanism of nitric oxide-induced surfactant dysfunction
210. Hemodynamic effects of inhaled nitric oxide in heart failure
211. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction
212. Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure
213. Influence of inhaled nitric oxide on systemic flow and ventricular filling pressure in patients receiving mechanical circulatory assistance
214. Hemodynamic and oxygenation changes induced by the discontinuation of low-dose inhalational nitric oxide in newborn infants
215. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide
216. Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure
217. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal
218. Primary pulmonary hypertension in childhood
219. Reversible cardio-pulmonary changes due to adeno-tonsilar hypertrophy
220. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial
221. Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia
222. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a
223. Mechanism of pulmonary vein stenosis in infants with normally connected veins
224. Recent advances in the treatment of pediatric pulmonary artery hypertension
225. Pulmonary vascular response to oxygen and inhaled nitric oxide
226. Primary pulmonary hypertension: natural history and the importance of thrombosis
227. Management of primary pulmonary hypertension
228. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
229. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension
230. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin
231. Hazards of diazoxide in pulmonary hypertension
232. Deleterious effects of hydrazaline in patients with pulmonary hypertension
233. Detrimental effects of verapamil in patients with primary pulmonary hypertension
234. Vasodilator therapy for primary pulmonary hypertension
235. Primary pulmonary hypertension ACCP consensus statement
236. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension
237. Inhaled prostacyclin in the treatment of pulmonary hypertension
238. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy
239. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group [see comments]
240. Vasodilator therapy for primary pulmonary hypertension in children
241. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects
242. Successful reversal of pulmonary hypertension in Eisenmenger complex
243. Double patch closure of ventricular septal defect with increased pulmonary vascular resistance
244. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue
245. Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group
246. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension
247. Low dose inhaled nitric oxide causing selective pulmonary vasodilation in child with idiopathic pulmonary hypertension
248. Selective and sustained pulmonary vasodilation with inhalational nitric oxide therapy in a child with idiopathic pulmonary hypertension
249. Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs, and humans
250. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells
251. Nitric oxide: physiology, pathophysiology, and pharmacology
252. Continuous nitric oxide inhalation reduces pulmonary arterial structural changes, right ventricular hypertrophy, and growth retardation in the hypoxic newborn rat
253. Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells
254. Nitric oxide inhalation decreases pulmonary artery remodeling in the injured lungs of rat pups
255. Inhaled nitric oxide and heparin for infantile primary pulmonary hypertension
256. Inhaled nitric oxide in neonatal Ebstein's anomaly [Abstract]
257. Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine
258. Inhaled nitric oxide in primary pulmonary hypertension-the 'perfect' pulmonary vasodilator
259. Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension
260. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers
261. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
262. Endothelin-1 and right-sided heart failure in rats: effects of an endothelin receptor antagonist on the failing right ventricle [In Process Citation]
263. The endothelin-A-receptor antagonist PD 180988 (CI-1034) selectively reverses the pulmonary vasoconstrictor response to hypoxia in the lamb [In Process Citation]
264. The prostacyclin-mimetic cicaprost inhibits endogenous endothelin-1 release from human pulmonary artery smooth muscle cells [In Process Citation]
265. Endothelin-A-receptor antagonist and oral prostacyclin analog are comparably effective in ameliorating pulmonary hypertension and right ventricular hypertrophy in rats [In Process Citation]
266. New hope for the treatment of pulmonary hypertension
267. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor
268. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease
269. Current perspectives on the use of gene therapy for hypertension
270. Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats
271. In vivo adenovirus-mediated endothelial nitric oxide synthase gene transfer ameliorates lung allograft ischemia-reperfusion injury
272. Cell-based gene transfer to the pulmonary vasculature: endothelial nitric oxide synthase overexpression inhibits monocrotaline-induced pulmonary hypertension [see comments]
273. Ischemia-induced coronary collateral growth is dependent on vascular endothelial growth factor and nitric oxide [In Process Citation]
274. Enhanced expression of vascular endothelial growth factor in pulmonary plexogenic arteriopathy due to congenital heart disease
275. Gene therapy for acute lung injury
276. Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats
277. New approaches to pulmonary hypertension: will therapies in mice work in humans? [Editorial; comment]
278. Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene
279. Role of atrial septostomy in the treatment of pulmonary vascular disease